Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FDA approves injectable drug to treat opioid-dependent patients
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
Can we safely target the WNT pathway?
Demyelinating Diseases: Myeloperoxidase as an Imaging Biomarker and Therapeutic Target.
Clinical assessment of noninvasive intracranial pressure absolute value measurement method.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
Newly diagnosed multiple sclerosis in state of Qatar.
Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation.
Endogeneous Remyelination: Findings in Human Studies.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
The role of complementary and alternative medicine in therapy of multiple sclerosis.
Id1 Expression Promotes T Regulatory Cell Differentiation by Facilitating TCR Costimulation.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification.
Conditional DC depletion does not affect priming of encephalitogenic Th cells in EAE.
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
Axonal damage in acute multiple sclerosis lesions.
Quality of life in the care home: a qualitative study of the perspectives of residents with multiple sclerosis.
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.

Pages